A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence

Next Previous
Trial Profile

A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Luspatercept (Primary)
  • Indications Anaemia; Myelofibrosis
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 31 Jan 2018 Planned End Date changed from 29 Jun 2019 to 21 Nov 2023.
    • 31 Jan 2018 Planned primary completion date changed from 8 Jun 2019 to 15 Jun 2019.
    • 28 Aug 2017 Planned End Date changed from 7 Nov 2023 to 29 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top